ClinicalTrials.Veeva

Menu

1,3,7-Trimethylxanthine as a Treatment of COVID-19: Results of a Controlled Study (TMX COVID)

P

Poitiers University Hospital

Status

Unknown

Conditions

Coronavirus Disease 2019

Treatments

Other: Data collection

Study type

Observational

Funder types

Other

Identifiers

NCT04395742
TMX COVID

Details and patient eligibility

About

This is observational study to assess the prognosis of patients hospitalized with COVID-19 confirmed by RT-PCR and exposed to trimethylxanthine (TMX).

Trimethylxanthine is the active molecule present in coffee. Due to the lack of etiologic treatments and considering interest about old treatments as an avenue for research, we conducted a comparative study aiming to evaluate the effect of 1,3,7-trimethylxanthine on COVID-19 infected patients. This is actually a study about methodology.

The objective of this study is therefore not to demonstrate the effect of the substance on the disease but the importance of a rigorous methodology in scientific research. This project is called "Method and Teaching of Scientific Studies".

Enrollment

93 estimated patients

Sex

All

Ages

18 to 100 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age > 18,
  • No Trimethylxanthine contraindications (defined as allergy, previous reported secondary effects),
  • Infectious Disease Unit admission.

Exclusion criteria

  • Secondary effects about Trimethylxanthine,
  • Refuse to participate

Trial design

93 participants in 2 patient groups

Coffee:1,3,7-trimethylxanthine
Treatment:
Other: Data collection
Tea and hot chocolate with milk
Treatment:
Other: Data collection

Trial contacts and locations

0

Loading...

Central trial contact

Alexandre BLEIBTREU; Paul ROBLOT

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems